This week, Eli Lilly and Company and Incyte announced the publication of the New England Journal of Medicine’s peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2). The Phase 3 study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and included 1,033 patients from 67 trial sites in eight countries. On November 19, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for baricitinib in combination with remdesivir in hospitalized patients with COVID-19 requiring supplemental oxygen, and the results of this study support that decision.
The use of baricitinib, in combination with remdesivir was authorized under the EUA, for hospitalized COVID-19 patients ages 2 years of age or older who required supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Anabela Cardoso, M.D., an author of the New England Journal of Medicine paper and Lilly global brand development lead, immunology, explained that currently, there is limited published data from placebo-controlled studies that assess treatment, symptoms...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).